Enterovirus A vaccine - Takeda

Drug Profile

Enterovirus A vaccine - Takeda

Alternative Names: Coxsackie virus vaccine - Takeda; EV71 vaccine; Hand, foot and mouth disease (HFMD) vaccine - Takeda; HFMDVax; INV 21; TAK-021

Latest Information Update: 23 Jul 2014

Price : $50

At a glance

  • Originator SingVax
  • Developer Takeda Pharmaceuticals USA
  • Class Enterovirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Enterovirus A infections

Most Recent Events

  • 31 May 2013 Inviragen has been acquired by Takeda Pharmaceuticals USA
  • 23 Mar 2012 CTP push (NCT01376479) - 700201139
  • 11 Mar 2012 Inviragen completes a phase I trial in healthy volunteers in Singapore (NCT01376479)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top